Examining the True Prevalence of Hypercortisolism and Its Impact on Managing Resistant Diabetes - Episode 5
Coexisting Cardiometabolic Conditions and Hypercortisolism
Medical experts discuss the implications of finding hypercortisolism in one-third of patients on three or more hypertension medications, the linkage between hypercortisolism and type 2 diabetes as presented in the ‘Pathologic Mechanisms of Hypercortisolism in Type 2 Diabetes’ session, and how hypercortisolism affects diabetes management, including the importance of addressing it and its consequences for patients with difficult-to-control diabetes.
Video content above is prompted by the following:
How do you interpret the finding that one-third of patients on three or more hypertension medications also had hypercortisolism?
- You presented the ‘Pathologic Mechanisms of Hypercortisolism in Type 2 Diabetes’ at the last ADA scientific session. Can you briefly explain the linkage between hypercortisolism and diabetes?
- How does hypercortisolism physiologically impact the management of T2D?
- Why is it important to address hypercortisolism? What are the consequences of untreated hypercortisolism in patients with diabetes?
- What are the clinical implications of this data? How does it inform or change the way we manage patients with difficult-to-control diabetes?
